Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation · Metastatic Prostate Neuroendocrine Carcinoma · Metastatic Prostate Small Cell Neuroendocrine Carcinoma · Stage IV Prostate Cancer AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States
Contact: Study coordinator (Site Public Contact) · becomingapatient@coh.org · 800-826-4673
Contact: Principal Investigator (Abhishek Tripathi)
Los Angeles General Medical Center, Los Angeles, California, United States
Contact: Study coordinator (Site Public Contact) · uscnorrisinfo@med.usc.edu · 323-865-0451
Contact: Principal Investigator (Jacek Pinski)
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Contact: Study coordinator (Site Public Contact) · 323-865-0451
Contact: Principal Investigator (Jacek Pinski)
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Northwestern University, Chicago, Illinois, United States
Contact: Study coordinator (Site Public Contact) · cancer@northwestern.edu · 312-695-1301
Contact: Principal Investigator (Maha H. Hussain)
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Contact: Study coordinator (Site Public Contact) · 859-257-3379
Contact: Principal Investigator (Zin W. Myint)
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Contact: Study coordinator (Site Public Contact) · 336-713-6771
Contact: Principal Investigator (Michael McCormack)
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
Contact: Principal Investigator (Edmund Folefac)
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Site Public Contact) · askmdanderson@mdanderson.org · 877-632-6789
Contact: Principal Investigator (Ana Aparicio)
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
Contact: Principal Investigator (John M. Floberg)
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
Contact: Principal Investigator (John M. Floberg)

Study leads

John M Floberg
Principal Investigator
JHU Sidney Kimmel Comprehensive Cancer Center LAO

View source on ClinicalTrials.gov